A Pilot Clinical Trial of the Cholecystokinin Receptor Antagonist MK‐329 in Patients with Advanced Pancreatic Cancer

MK-329 is a nonpeptidal, highly specific cholecystokinin (CCK) receptor antagonist, with affinity for pancreatic and gallbladder CCK receptors similar to CCK itself. MK-329 and its progenitor, asperlicin, can inhibit the growth of CCK receptor-positive human pancreatic cancer in athymic mice. Based on these activities and the ability of MK-329 to transiently increase food intake and enhance morphine analgesia in murine models, we conducted an open trial of MK-329 in 18 patients with advanced pancreatic cancer in whom the CCK receptor status of the tumors was unknown. Tumor response, pain control, and nutritional parameters (hunger rating, caloric intake, body weight, and anthropometrics) were serially assessed. The results of the study failed to demonstrate any impact of MK-329 on tumor progression, pain, or nutrition. Toxicity was mild and limited to nausea, vomiting, diarrhea, and abdominal cramps, with 17 of 18 patients able to tolerate treatment. While a role for MK-329 in the management of patients with advanced pancreatic cancer cannot be supported by the results of this trial, additional studies of this agent in patients with known CCK receptor-positive tumors, at escalated doses, and possibly in conjunction with other growth antagonists, appear warranted.

[1]  Jill P. Smith,et al.  CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium , 1991, Regulatory Peptides.

[2]  T. Solomon,et al.  Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA PaCa-2. , 1990, Gastroenterology.

[3]  B. Gertz,et al.  Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. , 1989, The Journal of clinical investigation.

[4]  R. Chang,et al.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. E. Evans,et al.  Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Hoeltzel,et al.  Combined effect of chronic bombesin and secretin or cholecystokinin on the rat pancreas , 1985, Peptides.

[7]  Karvetti Rl,et al.  Validity of the 24-hour dietary recall. , 1985 .

[8]  D. McGuire,et al.  The Measurement of Clinical Pain , 1984, Nursing research.

[9]  B. Nichols,et al.  A comparison of dietary methods in nutritional studies. , 1983, The American journal of clinical nutrition.

[10]  L. Johnson.  Effects of gastrointestinal hormones on pancreatic growth , 1981, Cancer.

[11]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[12]  L. Johnson,et al.  Growth of pancreas and gastrointestinal mucosa in antrectomized and gastrin-treated rats. , 1979, Endocrinology.

[13]  J. Elashoff,et al.  Interaction of caerulein and secretin on pancreatic size and composition in rat. , 1978, The American journal of physiology.

[14]  L. Johnson,et al.  New aspects of the trophic action of gastrointestinal hormones. , 1977, Gastroenterology.

[15]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.

[16]  R. Fisher,et al.  Oncogenes and the mitogenic signal pathway. , 1989, Important advances in oncology.

[17]  G. Poston,et al.  Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. , 1988, American journal of surgery.

[18]  M. Sporn,et al.  Peptide growth factors: current status and therapeutic opportunities. , 1987, Important advances in oncology.

[19]  A. Roberge,et al.  Dietary intake data: usefulness and limitations. , 1984, Progress in food & nutrition science.

[20]  S. Dudrick,et al.  Nutritional assessment : a manual for practitioners , 1983 .

[21]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[22]  C. Townsend,et al.  Stimulation of pancreatic cancer growth by caerulein and secretin , 1981 .

[23]  L. Johnson,et al.  Stimulation of pancreatic growth by secretin, caerulein, and pentagastrin. , 1980, Endocrinology.